Drug intelligence / Profile preview

lactobacillus plantarum CECT7484

Development stage: Unknown
Lead developer: AB-BIOTICS
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Lactobacillus plantarum CECT7484 (also known as Lactiplantibacillus plantarum CECT7484) is a specific probiotic bacterial strain developed by AB-Biotics. It is frequently utilized as a component of multi-strain probiotic formulations, such as the i3.1 blend, which also includes L. plantarum CECT7485 and Pediococcus acidilactici CECT7483. The strain has been clinically evaluated for its efficacy in managing Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD). Its mechanism of action involves the stabilization of the intestinal epithelial barrier, protection of the actin cytoskeleton, and modulation of CYP1A1 expression in epithelial cells, which helps reduce intestinal permeability and inflammation associated with mucosal mediators.

Other names: Lactiplantibacillus plantarum CECT7484

Beyond the preview

Go deeper on lactobacillus plantarum CECT7484.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lactobacillus plantarum CECT7484.

Explore the full profile